Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT06947512
Recruiting Not applicable

Personalization of Visual Characters and Text-to-Speech (TTS) to Support Learning in Students With Reading Difficulties

NCT06947512 · tracked via the Priya Life Science Italy tracker
Phase
Not applicable
Started
2023-02-16
Last updated
2025-05-04

Condition(s) studied

Developmental DyslexiaReading Problem

Investigational drug(s) / intervention(s)

Seleggo Test

Seleggo Test: Seleggo Test is a computerized procedure to identify the personalized visual and auditory parameters facilitating reading and writing for each participant. By applying these parameters to the visualization and to the TTS software during reading of school texts, the participants are expected to be facilitated in reading and understanding the text.

Study summary

Previous research has shown the importance of font type, size and spacing to facilitate text reading in dyslexia. A special automatized procedure was designed to select the most favorable parameters for both text visualization and text-to-speech (TTS) conversion to be used by students with reading difficulties. The validation of its outcomes will be carried out through a systematic comparison of the use of the personalized versus standard fonts and voices in reading and writing tests.

Eligibility

Sex
ALL
Min age
7 Years
Max age
15 Years
Healthy volunteers
Accepted
Inclusion Criteria (for TD group): * age 7-15 years * no history of reading difficulties * attends school in Italy Exclusion Criteria (for TD group): * special educational needs or diagnosis of neurodevelopmental disorders Inclusion Criteria (for DD group): * age 7-15 years * diagnosis of Developmental Dyslexia or Specific Reading Disorder * Attends school in Italy Exclusion Criteria (for DD group): * diagnosis of Intellectual Disability Inclusion Criteria (for SEN group): * age 7-15 years * reported by school to have significant difficulties in reading and writing * Attends school in Italy (at least 6 months continued schooling and exposure to the Italian language) Exclusion Criteria (for SEN group): * diagnosis of Intellectual Disability

Primary outcome measure(s)

Trial sites (3)

FacilityCityRegionStatus
IRCCS E. Medea, polo di Bosisio Parini Bosisio Parini LC Recruiting
IRCCS E.Medea, polo di Conegliano Conegliano TV Recruiting
Associazione La Nostra Famiglia Treviso TV Recruiting

More IRCCS Eugenio Medea trials in Italy

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06947512 on ClinicalTrials.gov ↗ ← All trials in Italy